Immutep Ltd
ASX:IMM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ceridian HCM Holding Inc
NYSE:DAY
|
US |
|
G
|
GIC Housing Finance Ltd
NSE:GICHSGFIN
|
IN |
|
P
|
Pearson PLC
XBER:PES
|
UK |
|
E
|
East Energy Resources Ltd
ASX:EER
|
AU |
|
Gujarat Toolroom Ltd
BSE:513337
|
IN |
|
SHL Telemedicine Ltd
SIX:SHLTN
|
IL |
|
Actelis Networks Inc
NASDAQ:ASNS
|
US |
|
K
|
Kumho HT Inc
KRX:214330
|
KR |
Immutep Ltd
Research & Development
Immutep Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immutep Ltd
ASX:IMM
|
Research & Development
-AU$82.7m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-26%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$60.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Research & Development
-AU$8m
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-67%
|
CAGR 10-Years
-14%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$171.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$65m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
-36%
|
|
Immutep Ltd
Glance View
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.
See Also
What is Immutep Ltd's Research & Development?
Research & Development
-82.7m
AUD
Based on the financial report for Dec 31, 2025, Immutep Ltd's Research & Development amounts to -82.7m AUD.
What is Immutep Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-26%
Over the last year, the Research & Development growth was -78%. The average annual Research & Development growth rates for Immutep Ltd have been -32% over the past three years , -37% over the past five years , and -26% over the past ten years .
